Daisuke Tomizawa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7908968/publications.pdf

Version: 2024-02-01

150	3,700	126858	155592
papers	citations	33 h-index	55 g-index

152	152	152	4589
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 2009, 114, 2489-2496.	0.6	383
2	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 2949-2962.	0.8	277
3	An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell, 2012, 22, 683-697.	7.7	213
4	Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia, 2007, 21, 2258-2263.	3.3	123
5	Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature Genetics, 2019, 51, 694-704.	9.4	97
6	Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-MÃ¼nster AML-study group. Blood, 2013, 122, 2704-2713.	0.6	86
7	t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica, 2014, 99, 865-872.	1.7	77
8	Acute myeloid leukemia in children: Current status and future directions. Pediatrics International, 2016, 58, 71-80.	0.2	71
9	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood, 2015, 126, 1575-1584.	0.6	69
10	Immunologically silent cancer clone transmission from mother to offspring. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17882-17885.	3.3	65
11	A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood, 2020, 136, 1813-1823.	0.6	61
12	Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984â€“1999. Leukemia, 2010, 24, 383-396.	3.3	60
13	Wholeâ€exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. British Journal of Haematology, 2016, 175, 476-489.	1.2	60
14	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood, 2011, 117, 7102-7111.	0.6	58
15	Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. British Journal of Haematology, 2011, 154, 363-372.	1.2	56
16	Hematopoietic stem cell transplantation for 30 patients with primary immunodeficiency diseases: 20 years experience of a single team. Bone Marrow Transplantation, 2006, 37, 469-477.	1.3	53
17	Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. Leukemia, 2013, 27, 2413-2416.	3.3	52
18	Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia. Leukemia, 2015, 29, 290-296.	3.3	51

#	Article	IF	Citations
19	Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in nonâ€Down syndrome. Genes Chromosomes and Cancer, 2017, 56, 394-404.	1.5	51
20	Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Advances, 2019, 3, 3157-3169.	2.5	51
21	Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia. Bone Marrow Transplantation, 2019, 54, 68-75.	1.3	49
22	Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood, 2006, 107, 4663-4665.	0.6	48
23	Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: Long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Pediatric Blood and Cancer, 2007, 49, 127-132.	0.8	48
24	Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan. Journal of Allergy and Clinical Immunology, 2015, 136, 1018-1024.	1.5	48
25	Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. International Journal of Hematology, 2013, 98, 578-588.	0.7	47
26	Identification of CD34+ and CD34â^' leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia. Blood, 2015, 125, 967-980.	0.6	47
27	Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood, 2012, 120, 1810-1815.	0.6	46
28	Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. Blood, 2018, 132, 1584-1592.	0.6	45
29	Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Childrenâ€™s Cancer Study Group (TCCSG) Study L04-16. International Journal of Hematology, 2018, 108, 98-108.	0.7	43
30	High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML. Leukemia, 2015, 29, 1076-1083.	3.3	42
31	Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: A single center experience. American Journal of Hematology, 2004, 76, 33-39.	2.0	41
32	High <scp>PRDM</scp>16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to <scp>FLT</scp>3â€<scp>ITD</scp>,<scp>KMT</scp>2Aâ€<scp>PTD</scp>, and <scp>NUP</scp>98â€<scp>NSD</scp>1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group <scp>AML</scp>â€05 trial. British Journal of Haematology, 2016, 172, 581-591.	1.2	41
33	Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan infant leukemia study group. Pediatric Blood and Cancer, 2009, 52, 808-813.	0.8	38
34	Recurrent RARB Translocations in Acute Promyelocytic Leukemia Lacking RARA Translocation. Cancer Research, 2018, 78, 4452-4458.	0.4	37
35	EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia. Haematologica, 2014, 99, e225-e227.	1.7	35
36	Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan. Pediatric Blood and Cancer, 2016, 63, 248-254.	0.8	33

#	Article	IF	Citations
37	Novel adopted immunotherapy for mixed chimerism after unrelated cord blood transplantation in Omenn syndrome. European Journal of Haematology, 2005, 75, 441-444.	1.1	32
38	Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol. International Journal of Hematology, 2014, 100, 171-179.	0.7	31
39	Recent progress in the treatment of infant acute lymphoblastic leukemia. Pediatrics International, 2015, 57, 811-819.	0.2	29
40	Kasabach-Merritt Phenomenon. Journal of Pediatric Hematology/Oncology, 2013, 35, 554-558.	0.3	28
41	Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial. Leukemia, 2015, 29, 2438-2441.	3.3	28
42	Analysis of serum soluble CD40 ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: platelet is a major source of serum sCD40L. European Journal of Haematology, 2005, 74, 54-60.	1.1	26
43	Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Blood Cancer Journal, 2014, 4, e226-e226.	2.8	26
44	Diplotype analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lymphoid neoplasms. Leukemia, 2018, 32, 2710-2714.	3.3	26
45	Cord blood transplantation is associated with rapid B-cell neogenesis compared with BM transplantation. Bone Marrow Transplantation, 2014, 49, 1155-1161.	1.3	24
46	Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 1515-1522.	2.0	24
47	Comparison of Intravenous with Oral Busulfan in Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Regimens for Pediatric Acute Leukemia. Biology of Blood and Marrow Transplantation, 2013, 19, 1690-1694.	2.0	20
48	Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. International Journal of Hematology, 2018, 107, 586-595.	0.7	20
49	Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. British Journal of Haematology, 2020, 188, 528-539.	1.2	20
50	Acute myeloid leukaemia with myelodysplastic features in children: a report of Japanese Paediatric Leukaemia/Lymphoma Study Group. British Journal of Haematology, 2014, 167, 80-86.	1.2	19
51	Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia. Blood Advances, 2018, 2, 2879-2889.	2.5	19
52	<scp>CSF</scp>3R and <scp>CALR</scp> mutations in paediatric myeloid disorders and the association of <scp>CSF</scp>3R mutations with translocations, including t(8; 21). British Journal of Haematology, 2015, 170, 391-397.	1.2	18
53	ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1â€RUNX1T1 and associated with a better prognosis. Genes Chromosomes and Cancer, 2017, 56, 382-393.	1.5	18
54	Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Childrenâ€™s Cancer Group Multi-Center Seamless Phase IIâ€“III Randomized Trial (JPLSG AML-12). Japanese Journal of Clinical Oncology, 2018, 48, 587-593.	0.6	18

#	Article	IF	Citations
55	Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols. International Journal of Hematology, 2015, 102, 318-326.	0.7	17
56	Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 2141-2147.	2.0	17
57	EWSR 1/ ELF 5 induces acute myeloid leukemia by inhibiting p53/p21 pathway. Cancer Science, 2016, 107, 1745-1754.	1.7	17
58	EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase. Haematologica, 2020, 105, 2118-2129.	1.7	17
59	Clinical features and outcome of MLL gene rearranged acute lymphoblastic leukemia in infants with additional chromosomal abnormalities other than 11q23 translocation. Leukemia Research, 2008, 32, 1523-1529.	0.4	16
60	Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. International Journal of Hematology, 2018, 107, 201-210.	0.7	15
61	RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis. Blood, 2018, 131, 2266-2270.	0.6	15
62	Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases. Bone Marrow Transplantation, 2019, 54, 393-401.	1.3	15
63	Invasive Subglottal Aspergillosis in a Patient with Severe Aplastic Anemia: A Case Report. Journal of Infection, 2002, 44, 198-201.	1.7	14
64	Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide and Antithymocyte Globulin from HLA-Mismatched Related Donors for Nonmalignant Diseases. Biology of Blood and Marrow Transplantation, 2020, 26, e286-e291.	2.0	14
65	Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis. International Journal of Hematology, 2021, 113, 134-144.	0.7	14
66	Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia. Pediatrics International, 2018, 60, 41-46.	0.2	13
67	Acute promyelocytic leukemia with a cryptic insertion of RARA into TBL1XR1. Genes Chromosomes and Cancer, 2019, 58, 820-823.	1.5	13
68	Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. Bone Marrow Transplantation, 2019, 54, 1489-1498.	1.3	13
69	Early coagulation disorder after allogeneic stem cell transplantation is a strong prognostic factor for transplantation-related mortality, and intervention with recombinant human thrombomodulin improves the outcome: a single-center experience. International Journal of Hematology, 2013, 98, 533-542.	0.7	12
70	Successful Treatment of Diffuse Large B-Cell Lymphoma in a Patient With Ataxia Telangiectasia Using Rituximab. Journal of Pediatric Hematology/Oncology, 2013, 35, 482-485.	0.3	12
71	Somatic MECOM mosaicism in a patient with congenital bone marrow failure without a radial abnormality. Pediatric Blood and Cancer, 2018, 65, e26959.	0.8	12
72	Multiplex fusion gene testing in pediatric acute myeloid leukemia. Pediatrics International, 2018, 60, 47-51.	0.2	12

#	Article	IF	Citations
73	Retrospective analysis of children with highâ€risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AMLâ€05 clinical trial. Pediatric Blood and Cancer, 2019, 66, e27875.	0.8	12
74	Negative CD19 expression is associated with inferior relapseâ€free survival in children with RUNX1â€RUNX1T1â€“positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AMLâ€05 study. British Journal of Haematology, 2019, 187, 372-376.	1.2	12
75	Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML â€05 study. British Journal of Haematology, 2019, 185, 284-288.	1.2	12
76	Hematopoietic stem cell transplantation for infants with high-risk KMT2A geneâ€“rearranged acute lymphoblastic leukemia. Blood Advances, 2021, 5, 3891-3899.	2.5	12
77	CXCR4Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatric Blood and Cancer, 2016, 63, 1394-1399.	0.8	11
78	The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AMLâ€05R study. Pediatric Blood and Cancer, 2021, 68, e28736.	0.8	11
79	A prospective study of allogeneic transplantation from unrelated donors for chronic granulomatous disease with target busulfan-based reduced-intensity conditioning. Bone Marrow Transplantation, 2019, 54, 168-172.	1.3	10
80	Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. Haematologica, 2021, , .	1.7	10
81	Pancytopenia presenting with monosomy 7 which disappeared after immunosuppressive therapy. Leukemia Research, 2004, 28, 315-319.	0.4	9
82	Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia. International Journal of Hematology, 2019, 110, 355-363.	0.7	9
83	Whole transcriptome sequencing reveals a KMT2Aâ€USP2 fusion in infant acute myeloid leukemia. Genes Chromosomes and Cancer, 2019, 58, 669-672.	1.5	9
84	Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases. Journal of Clinical Immunology, 2021, 41, 944-957.	2.0	9
85	Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing. Genes Chromosomes and Cancer, 2020, 59, 160-167.	1.5	8
86	Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without coreâ€binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Pediatric Blood and Cancer, 2020, 67, e28692.	0.8	8
87	A Prospective Viral Monitoring Study After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Nonmalignant Diseases. Transplantation and Cellular Therapy, 2021, 27, 872.e1-872.e8.	0.6	8
88	Favorable outcome in non-infant children with MLL-AF4-positive acute lymphoblastic leukemia: a report from the Tokyo Childrenâ€™s Cancer Study Group. International Journal of Hematology, 2015, 102, 602-610.	0.7	7
89	HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy. International Journal of Hematology, 2017, 105, 686-691.	0.7	7
90	Azacitidine successfully maintained the second remission in an infant with KMT2Aâ€rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation. Pediatric Blood and Cancer, 2017, 64, e26697.	0.8	7

#	Article	IF	Citations
91	Fludarabine, cytarabine, granulocyte colonyâ€stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia. Pediatrics International, 2017, 59, 1046-1052.	0.2	7
92	Fusion partnerâ€“specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. Blood Advances, 2020, 4, 4623-4631.	2.5	7
93	Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia. Blood Advances, 2022, 6, 3207-3219.	2.5	7
94	Translocation t(6;9)(p22;q34)/DEK-NUP214 rearranged Pediatric AML: A Retrospective International Study. Blood, 2012, 120, 538-538.	0.6	6
95	Quantitative assessment of copy number alterations by liquid biopsy for neuroblastoma. Genes Chromosomes and Cancer, 2022, 61, 662-669.	1.5	6
96	Respiratory syncytial virus infection in infants with acute leukemia: a retrospective survey of the Japanese Pediatric Leukemia/Lymphoma Study Group. International Journal of Hematology, 2015, 102, 697-701.	0.7	5
97	Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AMLâ€05R study. Pediatric Blood and Cancer, 2017, 64, e26491.	0.8	5
98	Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan. Leukemia Research, 2019, 87, 106263.	0.4	5
99	Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation. International Journal of Hematology, 2020, 111, 463-466.	0.7	5
100	Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. Leukemia, 2021, 35, 2508-2516.	3.3	5
101	Acute lymphoblastic leukemia in infants: A quarter century of nationwide efforts in Japan. Pediatrics International, 2022, 64, .	0.2	5
102	Nonconditioned ADA-SCID gene therapy reveals ADA requirement in the hematopoietic system and clonal dominance of vector-marked clones. Molecular Therapy - Methods and Clinical Development, 2021, 23, 424-433.	1.8	5
103	Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease. International Journal of Hematology, 2022, 115, 590-594.	0.7	5
104	Irreversible Leukoencephalopathy After Reduced-intensity Stem Cell Transplantation in a Dyskeratosis Congenita Patient With TINF2 Mutation. Journal of Pediatric Hematology/Oncology, 2013, 35, e178-e182.	0.3	4
105	Acute lymphoblastic leukemia in patients with Down syndrome with a previous history of acute myeloid leukemia. Pediatric Blood and Cancer, 2017, 64, e26411.	0.8	4
106	Down syndrome and AML: where do we go from here?. Blood, 2017, 129, 3274-3275.	0.6	4
107	Total body irradiation for hematopoietic stem cell transplantation during early childhood is associated with the risk for diabetes mellitus. Endocrine, 2018, 61, 76-82.	1.1	4
108	Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study. Bone Marrow Transplantation, 2021, 56, 1859-1865.	1.3	4

#	Article	IF	Citations
109	Twoâ€point blood sampling is sufficient and necessary to estimate the area under the concentrationâ€time curve for intravenous busulfan in infants and young children. Pediatric Blood and Cancer, 2021, 68, e29069.	0.8	4
110	NUDT15 variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia. Blood Advances, 2021, 5, 5420-5428.	2.5	4
111	Transient abnormal myelopoiesis in nonâ€<scp>D</scp>own syndrome neonate. Pediatrics International, 2015, 57, e14-7.	0.2	3
112	Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan. Pediatric Blood and Cancer, 2017, 64, e26475.	0.8	3
113	Tacrolimus blood concentration increase depends on administration route when combined with voriconazole in pediatric stem cell transplant recipients. Pediatric Transplantation, 2020, 24, e13619.	0.5	3
114	Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in Japan. Pediatric Blood and Cancer, 2020, 67, e28181.	0.8	3
115	Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AMLâ€05 study. British Journal of Haematology, 2021, 193, 176-180.	1.2	3
116	Acute Lymphoblastic Leukemia. , 2017, , 33-60.		3
117	Characteristics and outcomes of children with acute myeloid leukemia and Down syndrome who are ineligible for clinical trials due to severe comorbidities. Pediatric Blood and Cancer, 2019, 66, e27942.	0.8	2
118	Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia. EBioMedicine, 2021, 64, 103235.	2.7	2
119	Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1â€RUNX1T1 transcripts. British Journal of Haematology, 2021, 194, 414-422.	1.2	2
120	Successful Umbilical Cord Blood Transplantation With Reduced-intensity Conditioning for Acute Myeloid Leukemia in a Child With Shwachman-Diamond Syndrome. Journal of Pediatric Hematology/Oncology, 2021, 43, e414-e418.	0.3	2
121	Suppression of Let-7b MicroRNA and Enhanced Its Target genes in Infant Acute Lymphoblastic Leukemia with MLL Gene Rearrangements.. Blood, 2009, 114, 986-986.	0.6	2
122	CSF3R Gene Mutations In Myeloid Malignancy Of Childhood. Blood, 2013, 122, 1352-1352.	0.6	2
123	Postchemotherapy immune status in infants with acute lymphoblastic leukemia: A report from the JPLSG MLLâ€10 trial. Pediatric Blood and Cancer, 2022, 69, .	0.8	2
124	A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20). Japanese Journal of Clinical Oncology, 0, , .	0.6	2
125	Sudden unexpected death caused by infantile acute lymphoblastic leukaemia. Oxford Medical Case Reports, 2021, 2021, omab073.	0.2	1
126	Genetic features of precursor Bâ€cell phenotype Burkitt leukemia with IGHâ€MYC rearrangement. Cancer Reports, 2021, , e1545.	0.6	1

#	Article	IF	Citations
127	Excess Reduction of Anthracyclines Results in Inferior Event-Free Survival in Core Binding Factor Acute Myeloid Leukemia in Children; A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Blood, 2012, 120, 409-409.	0.6	1
128	Attempts to Optimize Post-Induction Treatment in Childhood Acute Myeloid Leukemia without Core Binding Factors: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Blood, 2012, 120, 3545-3545.	0.6	1
129	Comparison Of Intravenous With Oral Busulfan In Allogeneic Hematopoietic Stem Cell Transplantation With Myeloablative Conditioning Regimens For Pediatric Acute Leukemia. Blood, 2013, 122, 3397-3397.	0.6	1
130	Phase I/II Clinical Trial of Erwinia Asparaginase (ErwinaseR) in Combination with Prednisolone, Vincristine and Pirarubicin in Children and Young Adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL). Blood, 2014, 124, 3657-3657.	0.6	1
131	Childhood acute myeloid leukemia with 5q deletion and HNRNPH1-MLLT10 fusion: the first case report. Blood Advances, 2022, 6, 3162-3166.	2.5	1
132	A novel KMT2Aâ€ACTN2 fusion in infant Bâ€cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2019, 66, e27821.	0.8	0
133	Risk Stratification by MLL Gene Status and Outcome of Acute Lymphoblastic Leukemia in Infants: A Report from the Japan Infant Leukemia Study Group.. Blood, 2006, 108, 148-148.	0.6	0
134	Nation-Wide Survey of Infant Leukemia in Japan: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).. Blood, 2008, 112, 896-896.	0.6	0
135	Loss of Non-Inherited Maternal MHC and Materno-Fetal Transmission of p190 Type BCR-ABL Leukemia.. Blood, 2009, 114, 980-980.	0.6	0
136	Unrelated Umbilical Cord Blood Transplantation for Patients with Primary Immunodeficiency: A Report From the Registry of the Japan Cord Blood Bank Network. Blood, 2010, 116, 3524-3524.	0.6	0
137	Heterogeneity in Infants with Acute Myeloid Leukemia: Retrospective Analysis of a Japanese Nationwide Survey. Blood, 2011, 118, 1477-1477.	0.6	0
138	Refractory / Relapsed Myeloid Leukemia of Down Syndrome Is Resistant to Second-Line Chemotherapy and Hardly Salvaged by Hematopoietic Stem Cell Transplantation: A Retrospective Study by the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG). Blood, 2011, 118, 4276-4276.	0.6	0
139	Effect of KIR Ligand Mismatched SCT for Infantile ALL with MLL gene Rearrangement: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Blood, 2012, 120, 4543-4543.	0.6	0
140	Appropriate Dose Modification in Induction Therapy Is Essential for the Treatment of Infants with Acute Myeloid Leukemia; A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).. Blood, 2012, 120, 2615-2615.	0.6	0
141	Myelodysplasia-Related Changes Have Adverse Prognostic Significance in Children with Acute Myeloid Leukemia; A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).. Blood, 2012, 120, 2583-2583.	0.6	0
142	Low Frequency and Poor Prognosis Of MLL-Partial Tandem Duplications In Pediatric Acute Myeloid Leukemia Using MLPA Method: The Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 Trial. Blood, 2013, 122, 1374-1374.	0.6	0
143	Whole-Exome Resequencing Identifies Somatic Mutations Of BCOR and BCORL1 Transcriptional Corepressor Genes and Major Cohesin Complex Component Genes In Pediatric Acute Myeloid Leukemia. Blood, 2013, 122, 834-834.	0.6	0
144	Double CEBPA Mutations Are Not Associated With Favorable Clinical Outcome In Pediatric AML: A Report From The Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Blood, 2013, 122, 4942-4942.	0.6	0

#	Article	IF	Citations
145	Comprehensive Fusion Gene Analysis Of Pediatric Non-Down Syndrome Acute Megakaryoblasitc Leukemia. Blood, 2013, 122, 2646-2646.	0.6	0
146	Poor Prognosis With Different Induction Rate Was Observed In Children With Acute Myeloid Leukemia and FLT3-ITD According To The ITD/WT Allelic Ratio: A Result From The Japanese Pediatric Leukemia/Lymphoma Study Group. Blood, 2013, 122, 3891-3891.	0.6	0
147	Significance Of Minimal Residual Disease Detected By Multi-Color Flow Cytometry In Childhood Acute Myeloid Leukemia With The Intermideate-Risk Cytogenetics and Negative FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication: A Report Of The Tokyo Children's Cancer Study Group. Blood, 2013, 122, 1416-1416.	0.6	0
148	Acute Myeloid Leukemia. , 2017, , 61-85.		0
149	Infant ALL. , 2020, , 81-91.		0
150	Delay in diagnosis of blood disorders due to corticosteroid administration. Pediatrics International, 2022, 64, e14997.	0.2	0